Physician profile
Bashar Al-Turk
NPI 1699160408
$2,556.50
in general payments reported to CMS, 2019-2025
26 companies · $633 in 2025
The $633 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $412 · 2022: $73.75 · 2023: $762 · 2024: $676 · 2025: $633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,071.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,070.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $460.79 | 2021-2024 | Mitraclip |
| Pfizer INC. | $339.96 | 2023-2025 | |
| Novo Nordisk INC | $255.57 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $225.67 | 2023-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $220.49 | 2023-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $192.21 | 2024-2025 | Verquvo, Winrevair, Capvaxive |
| Actelion Pharmaceuticals US, INC. | $125.99 | 2023-2025 | Opsumit, Uptravi |
| Alnylam Pharmaceuticals INC. | $109.84 | 2023-2024 | Onpattro, Amvuttra |
| Novartis Pharmaceuticals Corporation | $108.32 | 2023-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $71.25 | 2022-2024 | Lifevest |
| Esperion Therapeutics, INC. | $49.05 | 2024-2025 | Nexletol |
| Boston Scientific Corporation | $48.68 | 2025 | General - Therapies |
| Janssen Pharmaceuticals, INC | $47.65 | 2023 | Xarelto |
| Lexicon Pharmaceuticals, INC. | $42.14 | 2023-2024 | Inpefa |
| Kiniksa Pharmaceuticals International, Plc | $35.05 | 2024 | Arcalyst |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $31.49 | 2022-2023 | Arcalyst |
| Edwards Lifesciences Corporation | $27.95 | 2024 | Sapien 3 Ultra Resilia |
| Astrazeneca Pharmaceuticals LP | $26.20 | 2025 | |
| Daiichi Sankyo INC. | $22.73 | 2022 | |
| United Therapeutics Corporation | $21.35 | 2023 | Tyvaso |
| Kls-Martin L.P. | $20.77 | 2025 | |
| Inspire Medical Systems, INC. | $17.92 | 2025 | Inspire |
| Kowa Pharmaceuticals America, INC. | $17.44 | 2024 | Livalo |
| Hydrofera LLC | $16.30 | 2025 | Hydrofera Blue |
| Bayer Healthcare Pharmaceuticals INC. | $15.23 | 2025 | |
| Analog Devices INC. | $6.46 | 2024 | Sensinel Cpm Wearable |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bashar Al-Turk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.